Home » Newsletters » BioWorld Science

BioWorld Science

April 18, 2005

View Archived Issues

Data on the survival effects of seocalcitol in advanced HCC

Remofovir reported to reduce viral load of patients with chronic hepatitis B

LB-80380 shows promise in the treatment of lamivudine-resistant hepatitis B

Idenix presents new data on drugs for chronic hepatitis

Good analgesic efficacy found with lamotrigine plus sertraline in neuropathic pain

Bioaccelerate Holdings and Symbollon enter agreement for IoGen

Cloretazine studied in phase I trial for pediatric brain tumors

SPI-153 enters phase II trial for BPH

Response submitted to FDA for Glumetza NDA

Priority review for SomatoKine

Orchid BioSciences seeks approval to change name to Orchid Cellmark

YM BioSciences to acquire Delex Therapeutics

Lilly licenses therapeutic proteins from Xencor

SCOLR Pharma adds three drug targets to CDT drug development program

Evotec OAI extends discovery chemistry agreement with Roche

Novel analgesic drugs presented in recent patent literature

Chemokine CCR5 modulators and their use as anti-HIV agents claimed by ViroChem and AstraZeneca

Acusphere amends phase III plans for AI-700

SDF-1 antagonist significantly reduces osteosarcoma metastases in animal model

Intranasal Technology inlicenses Aegis' Intravail drug delivery technology

ZSTK-474: a novel PI3K inhibitor with a promising preclinical profile

New indication approved for Hyzaar

Kos and Barr sign agreements to settle Niaspan patent litigation

Avastin improves progression-free survival in phase III breast cancer study

Albuferon safe and active in phase II trial in hepatitis C patients

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 17, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 17, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
European Commission floats multiple fixes for MDR, IVDR
BioWorld MedTech
The European Union’s struggles with regulations for devices and in vitro diagnostics seem virtually endless, but the European Commission floated a series of...
Apollo’s APL-4098 shows potent antileukemic effects
BioWorld Science
Apollo Therapeutics Ltd. has developed APL-4098, a small-molecule general control nonderepressible 2 (GCN2) inhibitor for the potential treatment of AML.